Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10037075 | 1.00 | TRPA1 (0.54) | TRPA1SIGMAR1MAPTRXFP1S1PR2 | |
| SCHEMBL16058107 | 0.98 | TRPA1 (0.51) | TRPA1SIGMAR1 | |
| SCHEMBL10473806 | 0.98 | TRPA1 (0.51) | TRPA1SIGMAR1 | |
| SCHEMBL560219 | 0.98 | TRPA1 (0.51) | TRPA1SIGMAR1 | |
| SCHEMBL10472566 | 0.92 | CYP2D6 (0.49) | SIGMAR1 | |
| SCHEMBL560468 | 0.92 | CYP2D6 (0.49) | SIGMAR1 | |
| SCHEMBL2571201 | 0.92 | CYP2D6 (0.49) | SIGMAR1 | |
| SCHEMBL11807780 | 0.89 | HDAC2 (0.50) | — | |
| SCHEMBL8716921 | 0.89 | HDAC2 (0.50) | — | |
| SCHEMBL8716910 | 0.89 | HDAC2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-4886624-A | STABLE; DRIERS | RHONE-POULENC, INC. (US) | 1989-12-12 | — | — | US | disclosed |
| US-4680411-A | Pyrano[2,3-g]indoles useful as anti-ulcerous, anti-inflammatory and antalgic agent | SOCIETE DE RECHERCHES INDUSTRIELLES (FR) | 1987-07-14 | — | — | US | disclosed |
| EP-0043752-B1 | PYRANOINDOLE DERIVATIVE AND PROCESS FOR ITS PREPARATION | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4436915-A | ANTIULCER, ANTIINFLAMMATORY | SOCIETE DE RECHERCHES INDUSTRIELLES (FR) | 1984-03-13 | — | — | US | disclosed |
| EP-0043752-A1 | Pyranoindole derivative and process for its preparation | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: (FR) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275032-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | TRPA1 2974/4885SIGMAR1 2740/4885MAPT 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.